The related deals between Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. announced April 6 appear to be a win for both sides. [See Deal] They extend and update a highly successful 10-year-old collaboration, essentially tweaking the original agreement’s terms in consideration of each partner’s current needs. [See Deal] At the same time, they recognize that the key product involved, the antipsychotic medication Abilify (aripiprazole), is reaching maturity.
Bristol-Myers Squibb and Otsuka Stabilize Their Bases
The related deals between Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. announced in April appear to be a win for both sides. They extend and update a highly successful 10-year-old collaboration, essentially tweaking the original agreement's terms in consideration of each partner's current needs. At the same time, they recognize that the key product involved, the antipsychotic medication Abilify, is reaching maturity.
More from Archive
More from In Vivo
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.
• By
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.